Drug Trial Radar · NCT06655246
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Last checked: Nov 21, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
135
Planned (sponsor's estimate)
Start
Mar 27, 2025
Primary completion
Jun 2029
Study completion Jun 2030
Sponsor
- Lead sponsor
- Kura Oncology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib as current or prior therapy, or are treatment naive.
Conditions
- Gastrointestinal Stromal Tumor (GIST)
- Gastrointestinal Stromal Cancer
- Gastrointestinal Stromal Neoplasm
- Gastrointestinal Stromal Tumor, Malignant
- Gastrointestinal Stromal Cell Tumors
Interventions
ziftomenibDrug
menin inhibitor
imatinib mesylateDrug
kinase inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity (DLT) (Dose Expansion)Time frame: Cycle 1 (first 28 day cycle)
- Descriptive statistics of Adverse Events (AEs)Time frame: First dose of ziftomenib up to and including 28 days after last dose of ziftomenib, or if the participant is lost to follow-up, whichever comes first
- Clinical Benefit Rate (CBR) (Dose Escalation and Dose Expansion Cohorts A and B only)Time frame: Up to 2 years following start of treatment with ziftomenib
- Overall Response Rate (ORR) (Dose Expansion Cohort C)Time frame: Up to 2 years following start of treatment with ziftomenib
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Mayo Clinic Cancer Center
Phoenix, Arizona · Recruiting
University of California, San Diego
La Jolla, California · Recruiting
University of Southern California
Los Angeles, California · Recruiting
University Of California, Irvine
Orange, California · Recruiting
Stanford Cancer Institute
Palo Alto, California · Recruiting
UCLA Santa Monica Medical Center
Santa Monica, California · Recruiting
University of Colorado Cancer Center
Aurora, Colorado · Recruiting
Sarah Cannon Research Institute
Denver, Colorado · Recruiting
Yale University School of Medicine
New Haven, Connecticut · Recruiting
Mayo Clinic Cancer Center
Jacksonville, Florida · Recruiting
University of Miami
Miami, Florida · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
University of Iowa
Iowa City, Iowa · Recruiting
Johns Hopkins University
Baltimore, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Harvard University
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Mayo Clinic Cancer Center
Rochester, Minnesota · Recruiting
Memorial Sloan-Kettering Cancer Center
New York, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Ohio State University
Columbus, Ohio · Recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
Thomas Jefferson University
Philadelphia, Pennsylvania · Recruiting
Temple University Health System
Philadelphia, Pennsylvania · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Sarah Cannon Research Institute
Dallas, Texas · Recruiting
University of Texas
Houston, Texas · Recruiting
University of Texas Health Science Center
San Antonio, Texas · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.